To view this email as a web page, click here.
 
How payers are responding to growing orphan drug costs
From our sister publication, Managed Healthcare Executive: Payers are stepping up efforts to manage the cost and utilization of orphan drug treatments.
Read more
 
Pharmacy chains respond to Trump drug pricing plan
Major drug store chains—along with pharmacist organizations—respond to President Trump’s new plan to lower prescription drug prices.
Read more
 
Breakthrough childhood MS drug okayed
FDA approved fingolimod (Gilenya) for the treatment of children and adolescents who have relapsing forms of multiple sclerosis—the first disease-modifying therapy indicated for these patients.
Read more
 
ADVERTISEMENT
Ad description here
 

This is a post-only, outbound email. Please do not reply to this email as we will be unable to respond to your reply. Please use the links provided if you have questions or concerns regarding this email or your subscription.